RaQualia Pharma
4579.TTSE GROWTHPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Operating income | ¥484m | −¥213m | −¥337m | ¥866m | ¥708m | — |
| Ordinary income | ¥438m | −¥362m | −¥293m | ¥904m | ¥864m | −¥528m |
| Net income (owners) | ¥273m | −¥495m | −¥324m | ¥723m | ¥756m | −¥607m |
| Total assets | ¥10.5bn | ¥9.7bn | ¥6.9bn | ¥6.3bn | ¥5.2bn | ¥4.3bn |
| Net assets / equity | ¥6.9bn | ¥5.6bn | ¥6.1bn | ¥5.5bn | ¥4.8bn | ¥4.0bn |
| Operating cash flow | −¥354m | ¥181m | −¥719m | ¥1.5bn | ¥366m | −¥289m |
| EPS (basic) | ¥11.53 | ¥-22.87 | ¥-14.98 | ¥34.5 | ¥36.07 | ¥-28.97 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 3
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 63 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 62 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 63 figures · EDINET |
24 more reports are still being processed.